Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 27 | 2024 | 3636 | 4.460 |
Why?
|
Sulfonamides | 10 | 2024 | 1982 | 1.680 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 1560 | 1.530 |
Why?
|
Trisomy | 2 | 2024 | 260 | 1.510 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 384 | 1.320 |
Why?
|
Asparaginase | 2 | 2024 | 240 | 1.040 |
Why?
|
Antibodies, Bispecific | 2 | 2023 | 204 | 0.860 |
Why?
|
Myelodysplastic Syndromes | 5 | 2024 | 1404 | 0.800 |
Why?
|
Staurosporine | 2 | 2021 | 241 | 0.780 |
Why?
|
Dioxygenases | 1 | 2024 | 353 | 0.770 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 308 | 0.740 |
Why?
|
fms-Like Tyrosine Kinase 3 | 6 | 2024 | 496 | 0.720 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 292 | 0.700 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 11872 | 0.690 |
Why?
|
Pyrazines | 2 | 2024 | 1204 | 0.680 |
Why?
|
Neutropenia | 2 | 2022 | 894 | 0.650 |
Why?
|
Depsipeptides | 1 | 2019 | 95 | 0.640 |
Why?
|
Cytarabine | 5 | 2024 | 696 | 0.630 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2019 | 125 | 0.590 |
Why?
|
Gastritis | 1 | 2019 | 199 | 0.570 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 210 | 0.570 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2023 | 678 | 0.550 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1061 | 0.510 |
Why?
|
Mutation | 10 | 2024 | 30213 | 0.460 |
Why?
|
Venous Thromboembolism | 2 | 2024 | 1882 | 0.450 |
Why?
|
Lymphoma | 1 | 2023 | 1900 | 0.440 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2024 | 5753 | 0.400 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4522 | 0.380 |
Why?
|
Prognosis | 11 | 2024 | 29948 | 0.360 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 1642 | 0.340 |
Why?
|
DNA Methylation | 1 | 2024 | 4427 | 0.330 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5690 | 0.330 |
Why?
|
Remission Induction | 4 | 2024 | 2413 | 0.320 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 9611 | 0.290 |
Why?
|
Aniline Compounds | 2 | 2024 | 1079 | 0.290 |
Why?
|
Humans | 52 | 2024 | 766766 | 0.280 |
Why?
|
Echocardiography | 1 | 2019 | 5037 | 0.260 |
Why?
|
Risk Assessment | 3 | 2023 | 24295 | 0.250 |
Why?
|
Leukemia | 2 | 2024 | 1521 | 0.240 |
Why?
|
Salvage Therapy | 2 | 2022 | 1274 | 0.230 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2024 | 42 | 0.220 |
Why?
|
Recurrence | 5 | 2024 | 8507 | 0.220 |
Why?
|
Daunorubicin | 1 | 2024 | 157 | 0.220 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 13643 | 0.220 |
Why?
|
Chromosome Inversion | 1 | 2024 | 119 | 0.220 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4278 | 0.220 |
Why?
|
Idarubicin | 1 | 2023 | 59 | 0.220 |
Why?
|
p21-Activated Kinases | 1 | 2024 | 127 | 0.220 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 322 | 0.210 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2024 | 950 | 0.210 |
Why?
|
Sunlight | 1 | 2024 | 336 | 0.200 |
Why?
|
Young Adult | 8 | 2024 | 59939 | 0.190 |
Why?
|
Review Literature as Topic | 1 | 2023 | 297 | 0.190 |
Why?
|
Karyotyping | 1 | 2024 | 1176 | 0.190 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 187 | 0.190 |
Why?
|
Retrospective Studies | 16 | 2024 | 81635 | 0.180 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1926 | 0.170 |
Why?
|
Anemia, Aplastic | 1 | 2022 | 231 | 0.170 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 176 | 0.170 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2021 | 451 | 0.170 |
Why?
|
Azacitidine | 1 | 2021 | 335 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2022 | 251 | 0.170 |
Why?
|
Glucose-6-Phosphate | 1 | 2019 | 29 | 0.160 |
Why?
|
Adult | 16 | 2024 | 223307 | 0.160 |
Why?
|
Leukemia, Myeloid | 1 | 2022 | 695 | 0.160 |
Why?
|
Middle Aged | 18 | 2024 | 223257 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 723 | 0.160 |
Why?
|
Lymphoma, Follicular | 1 | 2023 | 460 | 0.160 |
Why?
|
ras Proteins | 1 | 2024 | 1055 | 0.160 |
Why?
|
Aged | 15 | 2024 | 171343 | 0.160 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1762 | 0.160 |
Why?
|
Aged, 80 and over | 9 | 2024 | 59550 | 0.150 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 230 | 0.150 |
Why?
|
Retreatment | 1 | 2019 | 598 | 0.150 |
Why?
|
Disease-Free Survival | 3 | 2023 | 6850 | 0.140 |
Why?
|
Adolescent | 7 | 2024 | 88904 | 0.140 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 180 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 685 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2020 | 444 | 0.140 |
Why?
|
Male | 18 | 2024 | 364142 | 0.130 |
Why?
|
Postoperative Complications | 1 | 2019 | 15831 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 646 | 0.130 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8540 | 0.130 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10264 | 0.130 |
Why?
|
Helicobacter pylori | 1 | 2019 | 380 | 0.120 |
Why?
|
Helicobacter Infections | 1 | 2019 | 390 | 0.120 |
Why?
|
Chromosome Aberrations | 1 | 2021 | 1776 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2022 | 1172 | 0.120 |
Why?
|
Survival Rate | 3 | 2024 | 12825 | 0.110 |
Why?
|
Methotrexate | 1 | 2020 | 1719 | 0.110 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1434 | 0.110 |
Why?
|
Disease Management | 1 | 2024 | 2533 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2948 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 818 | 0.110 |
Why?
|
Child | 5 | 2024 | 80668 | 0.110 |
Why?
|
Nuclear Proteins | 2 | 2024 | 5795 | 0.100 |
Why?
|
Incidence | 4 | 2024 | 21525 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2024 | 2747 | 0.100 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3439 | 0.100 |
Why?
|
Abdominal Pain | 1 | 2019 | 1069 | 0.100 |
Why?
|
Bone Marrow | 1 | 2023 | 2926 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2143 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6512 | 0.100 |
Why?
|
Female | 15 | 2024 | 396520 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2446 | 0.100 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1998 | 0.100 |
Why?
|
Dyspnea | 1 | 2019 | 1352 | 0.100 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3935 | 0.090 |
Why?
|
Pulmonary Artery | 1 | 2019 | 1938 | 0.090 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2232 | 0.090 |
Why?
|
Israel | 2 | 2023 | 726 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2030 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3853 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1946 | 0.070 |
Why?
|
Cyclopentanes | 1 | 2007 | 87 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2186 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2019 | 5329 | 0.060 |
Why?
|
Cohort Studies | 4 | 2024 | 41710 | 0.060 |
Why?
|
Body Mass Index | 1 | 2023 | 13050 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5194 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 142 | 0.060 |
Why?
|
Melanoma, Experimental | 1 | 2007 | 557 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2007 | 616 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6550 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 65273 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5387 | 0.050 |
Why?
|
Oxidative Phosphorylation | 1 | 2024 | 502 | 0.050 |
Why?
|
Risk Factors | 3 | 2024 | 74881 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 286 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 13090 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39309 | 0.050 |
Why?
|
Signal Transduction | 1 | 2024 | 23619 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5182 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2020 | 1062 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13485 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8045 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1733 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1609 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20708 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2019 | 597 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3607 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2022 | 1791 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2448 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22350 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1012 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2021 | 1635 | 0.030 |
Why?
|
Anticoagulants | 2 | 2021 | 4855 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2060 | 0.030 |
Why?
|
Causality | 1 | 2019 | 1252 | 0.030 |
Why?
|
Phosphorylation | 1 | 2024 | 8307 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 4860 | 0.030 |
Why?
|
Age Factors | 2 | 2019 | 18397 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2022 | 3721 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2023 | 2823 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 1203 | 0.020 |
Why?
|
Mitochondria | 1 | 2024 | 3677 | 0.020 |
Why?
|
Cell Line | 1 | 2024 | 15563 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3464 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3824 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26310 | 0.020 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1659 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5618 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4252 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4747 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14762 | 0.020 |
Why?
|
Oxylipins | 1 | 2007 | 54 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10619 | 0.020 |
Why?
|
Acetates | 1 | 2007 | 314 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15835 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10580 | 0.010 |
Why?
|
Cytokines | 1 | 2020 | 7438 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2007 | 718 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8735 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15416 | 0.010 |
Why?
|
Mice | 2 | 2024 | 81889 | 0.010 |
Why?
|
Stroke | 1 | 2019 | 9741 | 0.010 |
Why?
|
Animals | 2 | 2024 | 168930 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 54871 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 17088 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2007 | 22352 | 0.000 |
Why?
|